Abstract: Guardrail, guardrail terminal, and support post designs that improve control of a vehicle during collisions are described. The disclosed designs also reduce the likelihood of intrusion into vehicle systems and the occupant compartment(s). Embodiments include folding and/or flattening of the guardrail and controlling the folded and flattened guardrail to avoid intrusion into the vehicle. Other embodiments include containing the guardrail in an impact head of a guardrail terminal, which also avoids vehicle intrusion.

Abstract: A battery powered fluid sprayer includes a battery mounted to a vertically extending wall of the fluid sprayer. The battery powers an electric motor to power a pump to pump fluid to a spray gun for spraying. The battery is disposed within a battery chamber enclosed by a door. The battery is suspended above a base of the battery chamber to isolate battery from any fluid that may enter the chamber.

Abstract: The present disclosure provides pharmaceutical compositions that include one or more selective estrogen receptor modulator(s) (SERM(s), e.g., Lasofoxifene) and four or more pharmaceutically acceptable excipients. The pharmaceutical compositions may be able to form nanodroplets (e.g., by self-nanoemulsifying) in vaginal fluid and to deliver the one or more SERM(s) to the vagina of a female subject. The pharmaceutical compositions may be useful in treating or preventing vulvovaginal atrophy, dyspareunia, sexual dysfunction, osteoporosis, or breast cancer in a female subject.

Abstract: The present disclosure provides pharmaceutical compositions that include one or more selective estrogen receptor modulator(s) (SERM(s), e.g., Lasofoxifene) and four or more pharmaceutically acceptable excipients. The pharmaceutical compositions may be able to form nanodroplets (e.g., by self-nanoemulsifying) in vaginal fluid and to deliver the one or more SERM(s) to the vagina of a female subject. The pharmaceutical compositions may be useful in treating or preventing vulvovaginal atrophy, dyspareunia, sexual dysfunction, osteoporosis, or breast cancer in a female subject.

Abstract: A wire reel holder and dispensing assembly is provided for transporting, holding, and dispensing wire from a wire reel. The holder and assembly includes an elongated shaft configured for insertion through a wire reel. Each of a pair of end members has a polygonal outer perimeter edge and a central opening. The shaft is slidably insertable through the central opening of each end member positioning the end members at each end of the wire reel. Each end member is securable to the shaft to hold the wire reel in a static position along a length of the shaft and prevent rolling of the wire reel on the shaft. A holding assembly is provided for connecting the shaft, end members and wire reel to a vehicle.

Abstract: A wire reel holder and dispensing assembly is provided for transporting, holding, and dispensing wire from a wire reel. The holder and assembly includes an elongated shaft configured for insertion through a wire reel. Each of a pair of end members has a polygonal outer perimeter edge and a central opening. The shaft is slidably insertable through the central opening of each end member positioning the end members at each end of the wire reel. Each end member is securable to the shaft to hold the wire reel in a static position along a length of the shaft and prevent rolling of the wire reel on the shaft. A holding assembly is provided for connecting the shaft, end members and wire reel to a vehicle.

Abstract: This invention relates to methods, pharmaceutical compositions and kits useful in treating female sexual dysfunction and the use of an estrogen agonist/antagonist for the manufacture of a medicament for the treatment of female sexual dysfunction. The compositions are comprised of an estrogen agonist/antagonist as a first active ingredient and a cyclic guanosine 3?,5?-monophosphate elevator as a second active component and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

Abstract: A load moving system includes a pair of lifting assemblies. The assemblies are positioned on opposite sides of a load to be carried. Each of the assemblies includes a plate. A vertical wall is attached to the plate and the plate extends forward from a bottom edge of the vertical wall. The plate is extendable under the load and the vertical wall is positionable against the load. An upper wall is attached to an upper portion of the vertical wall and extends rearward of the vertical wall. A pair of wheel assemblies is provided. Each of the wheel assemblies is positioned below and is rotatably coupled to the upper wall. A pair of support posts is attached to and extends upwardly from the upper wall. A coupling assembly releasably couples the support posts to the load.

Abstract: This invention relates to methods and kits useful for improving or maintaining urogenital health using an estrogen agonist/antagonist. The methods of treatment are effective for improving or maintaining urogenital health while substantially reducing the concomitant liability of adverse effects associated with estrogen administration. This invention also relates to methods of assessing vaginal health.

Abstract: This invention relates to methods, pharmaceutical compositions and kits useful in treating female sexual dysfunction and the use of an estrogen agonist/antagonist for the manufacture of a medicament for the treatment of female sexual dysfunction. The compositions are comprised of an estrogen agonist/antagonist as a first active ingredient and a cyclic guanosine 3?,5?-monophosphate elevator as a second active component and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

Abstract: Pharmaceutical combination compositions including certain estrogen agonists/antagonists and prostaglandins or prostaglandin agonists/antagonists. The compositions are useful for the treatment of bone disorders including osteoporosis.

Abstract: The present invention relates to pharmaceutical compositions, kits and methods comprising combinations of (?)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or nontoxic pharmacologically acceptable acid addition salts thereof and estrogens. The present invention also relates to pharmaceutical compositions, kits and methods comprising combinations of (?)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or nontoxic pharmacologically acceptable acid addition salts thereof, estrogens and progestins.

Abstract: Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I wherein the variables A, B, Y, D, Z1, G and e are as described herein.

Abstract: This invention relates to methods, pharmaceutical compositions and kits useful in promoting bone formation and/or preventing bone loss and lowering blood cholesterol. The compositions are comprised of an estrogen agonist/antagonist as a first active component and a statin as a second active component and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

Abstract: Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

Abstract: This invention relates to methods, pharmaceutical compositions and kits useful in promoting bone formation and/or preventing bone loss and lowering blood cholesterol. The compositions are comprised of an estrogen agonist/antagonist as a first active component and a statin as a second active component and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

Abstract: This invention is directed to methods of treating conditions which present with low bone mass, particularly osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis, or prosthetic ingrowth comprising administering prostaglandin agonists which are EP4 receptor selective prostaglandin agonists. This invention is especially directed to those methods wherein the EP4 receptor selective agonist is a compound of Formula I: wherein the variables are as defined in the specification.

Abstract: This invention relates to methods, pharmaceutical compositions and kits useful in treating conditions responsive to estrogen by the administration of estrogen agonists/antagonists. Conditions responsive to the compositions and methods include rheumatoid arthritis, colon cancer, tissue wounds, skin wrinkles and cataracts. The compositions are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I 1